This news should not be misinterpreted as negative. It could even turnout to be very good news for Todos if the two SAEs that caused the pause were given placebo instead of Tollovir. Since the trial is randomized, double-blind, placebo-controlled, the company won't know the cause of the SAEs until they review the interim data.